-
2023 CASH Professor Liu Qiqi: Carefully explore the treatment methods of leukemia and help the development of the field of hematological oncology
Time of Update: 2023-02-01
He has made great achievements in the fields of molecular pathogenesis of leukemia, tumor immunotherapy, hematopoietic stem cell transplantation and infection prevention and treatment in immunocompromised peopleHe has presided over 3 national key research and development programs, 3 863 programs, 10 national natural science including major/key projects and more than 20 provincial and ministerial projects.
-
Hypoxia-activated precursor drugs sensitized by nano-photosensitizers for precise treatment of gliomas
Time of Update: 2023-02-01
Conclusion of the study In summary, the biologically safe iRGD@ZnPc+TPZ nanomaterials constructed in this study can pass through the BBB, target penetration and enrich into the deep tumor, promote hypoxia activation of TPZ through PDT, realize the intelligent combination of PDT and chemotherapy, realize the precise delivery of drugs to the brain, significantly inhibit the growth of glioma, reduce toxic side effects, and prolong the survival time of glioma-loaded mice.
-
The father of CAR-T new research! CAR-T cell therapy can eliminate residual cancer cells after solid tumors and prevent cancer recurrence
Time of Update: 2023-02-01
This article is the original of Translational Medicine Network, please indicate the source for reprintingAuthor: MiaA preclinical study by researchers at the University of Pennsylvania's Perelman School of Medicine says CAR-T-cell therapy, a way to reprogram a patient's own immune cells to attack their blood cancers, may enhance the effectiveness of surgery for solid tumors.
-
Brain stem tumors in children can exacerbate cognitive, emotional, and behavioral impairment
Time of Update: 2023-02-01
Research methods The investigators included 172 children with brainstem tumors aged 4-18 years as the study group and 46 age-matched healthy children as the control group.
Research methods The investigators included 172 children with brainstem tumors aged 4-18 years as the study group and 46 age-matched healthy children as the control group.
-
Canadian guidelines for molecular detection of central nervous system tumors in adolescents and young adults
Time of Update: 2023-02-01
In the absence of necrosis or microangiogenesis, genetic alterations such as EGFR amplification, telomerase reverse transcriptase (TERT) promoter mutations, and/or chromosome 7 amplification and chromosome 10 deletion (Chr7+/10-) should be assessed, and if more than one of these changes is present, the tumor should be classified as IDH wild-type glioblastoma.
-
Protecting the source and ensuring a sufficient amount of chemotherapy, traraciclib helps patients achieve excellent results!
Time of Update: 2023-02-01
B cT4N3M1cMetastasis of both hilar and mediastinal lymph nodesMultiple lymph node metastases in the hilar region of the liverLeft pleural metastasisAccording to the "Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of Small Cell Lung Cancer", Dr. Meng Chong chose the first-line treatment regimen of etoposide combined with carboplatin for the patient.
-
Advances in targeted therapy for liver cancer
Time of Update: 2023-02-01
Liver cancer is one of the most common malignant tumors, it is reported that there will be 431,000 new cases of liver cancer and 412,000 deaths in China in 2022, due to the high rate of hepatitis B in
-
Precise targeting, rebirth Professor Qi Changsong: Larotinib helps pan-tumor treatment move towards a new era of precision, order and combination
Time of Update: 2023-02-01
Fig. 4 Safety data of larotinibAuthoritative guidelines recommend larotinibBased on the good survival benefit of larotinib, the National Comprehensive Cancer Network (NCCN) clinical practice guidelines recommend lalotinib for the treatment of NTRK gene fusion-positive non-small cell lung cancer, colorectal cancer, thyroid cancer, soft tissue sarcoma and other tumors.
-
The impasse was hard to break, and Arch Oncology ended its CD47 antibody development journey
Time of Update: 2023-02-01
com/scoop-roche-backed-startup-gives-up-on-cd47-as-ceo-most-employees-leave/ tens of billions of dollars to enter the gambling, the lure of CD47 targets and "traps"/amino finance Note: This article does not contain any medical views or investment adviceHowever, safety concerns have always been present, and the news of several clinical suspension of CD47 products last year has once again called into question its druggability.
-
FDA Approval Annual Inventory (Part II) | Lung Cancer and Melanoma
Time of Update: 2023-02-01
For more information, click here: FDA Alert| Selpercatinib Accelerates Approval for RET Gene Fusion-Positive Locally Advanced or Metastatic Solid TumorsJanuary 11FDA approval of cemiplimab-RWLC in combination with platinum-based chemotherapy for the treatment of advanced adult NSCLC patients without EGFR, ALK, or ROS1 mutations is based on the 16113 (NCT03409614) study.
-
The Lancet: Faviravir early antiviral therapy reduces the risk of death in high-risk patients!
Time of Update: 2023-02-01
A multicenter, open-label, randomized controlled study conducted from May 2020 to May 2021, including 499 patients with suspected or confirmed COVID-19 who were admitted to hospitals in the United Kingdom, Brazil and Mexico, were randomized in a 1:1 basis, with the study group receiving faviravir + standard care (SoC) and the control group receiving only standard care.
-
【Adv. Sci】Shandong University Chubo and other teams discovered a novel anti-ferrozotic pathway that promotes tumor cell growth
Time of Update: 2023-02-01
This article is the original of Translational Medicine Network, please indicate the source for reprintingWritten by SophiaIt is known that the conversion of methionine to cysteine can protect tumor cells from iron death during cysteine starvation through transamination.
-
Professor Wang Ying: Count the progress of TNBC 2022 treatment, see where the future development direction is?
Time of Update: 2023-02-01
Figure 1 EFS analysis results for different RCB categoriesThis year's SABCS Annual Meeting also reported a real-world study of adverse effects as standard therapy for patients with early-stage TNBC according to the KEYNOTE-522 protocol⁹, which found a higher incidence of ≥grade 3 adverse events (AEs) and lower pCR rates than in the KEYNOTE-522 trial.
-
【Immunity】A new combination of drugs combined with anti-PD-L1! Studies have found that this combination can overcome cancer immunotherapy resistance
Time of Update: 2023-02-01
Fluorescence microscopy of controlled tumors with PD1-IL2v for the treatment of tumorsThe researchers combined the immune cytokine PD1-IL2v with the immune checkpoint inhibitor anti-PD-L1 to enhance anti-tumor immunity against immunotherapy-resistant tumors.
-
Relationship between epilepsy and glioma prognosis
Time of Update: 2023-02-01
Research methods The authors included the clinical data of 485 glioma patients in Nanjing Brain Hospital and conducted four regular follow-ups to analyze the clinical characteristics of glioma patients with seizures and their relationship with survival.
-
Professor Shi Meiqi: The rising star of immunotherapy, and adebelimab has created a miracle of life for SCLC patients
Time of Update: 2023-02-01
Small cell lung cancer (SCLC) accounts for about 15%¹ of lung cancer incidence¹, and its high degree of malignancy, fast growth, and easy metastasis are a "difficult bone" in lung cancer treatment. Fo
-
Efficacy of dual antiepileptic drugs in patients with gliomas
Time of Update: 2023-02-01
In summary, this retrospective observational cohort study showed that LEV+VPA was more effective in antiepileptic than other dual therapy combinations of ASM plus LEV or VPA, but with similar levels of drug toxicity.
-
Comprehensive combing When "lymphoma" meets "new crown", how to deal with it?
Time of Update: 2023-02-01
02 COVID-19 treatment recommendations for lymphoma patientsAccording to the "Diagnosis and Treatment Plan for Novel Coronavirus Infection (Trial Version 10)", the new crown treatment methods include: general treatment, antiviral therapy (nematevir tablets/ritonavir tablets combination package, azvudine tablets, monoravir capsules, ambavirumab/romisivimab injection, etc.
-
Optimal Selection for PSA and Testosterone Management in Prostate Cancer Survival and Quality of Life Improvement
Time of Update: 2023-02-01
Execution:RudolfThis platform is designed to deliver more medical information to healthcare professionals.
Execution:RudolfThis platform is designed to deliver more medical information to healthcare professionals.
This platform is designed to deliver more medical information to healthcare professionals.
-
CA(IF=286) Latest Review! Comprehensive summary of the development of CAR-T cell therapy for myeloma (worth collecting)
Time of Update: 2023-02-01
However, their efficacy is limited by excessive toxicity and a similar risk of recurrence to other therapies such as CAR-T cell therapy, antibody-drug conjugates, and bispecific T cell zygotes, which show great promise in altering the prospect of RRMM and that the use of CAR T cells in myeloma is influenced by their use in other B-cell lymphocytic malignancies such as acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL)) Inspired by remarkable success.
